Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
INDERIDE LA 120/50 vs LABETALOL HYDROCHLORIDE IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Category C
Category A/B
Beta-Blocker/Diuretic Combination
Alpha/Beta-Blocker